Evidence map›Paper›PMID 36961030›Full record

ArticlePharmacy (Basel, Switzerland)2023

Community-Centered Patient Journey Map in Opioid Use Disorder: A Tool to Address Compassion Fatigue among Community Pharmacists.

Kenneth Charles Hohmeier, Alina Cernasev, Christina Leibold, Todd M Moore, Erica Schlesinger, Gerald Cochran, Ileana Arce, Wesley Geminn, Marie Chisholm-Burns

Open access · goldFull text read
In one paragraph

Article in Pharmacy (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Kenneth Charles HohmeierDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Nashville, TN 37211, USA.ORCID 0000-0002-0060-4643
Alina CernasevDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Nashville, TN 37211, USA.
Christina LeiboldDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Nashville, TN 37211, USA.
Todd M MooreDepartment of Psychology, University of Tennessee, Knoxville, TN 37996, USA.
Erica SchlesingerTennessee Department of Mental Health & Substance Abuse Services, Nashville, TN 37243, USA.
Gerald CochranDivision of Epidemiology, University of Utah, Salt Lake City, UT 84112, USA.
Ileana ArceTennessee Department of Mental Health & Substance Abuse Services, Nashville, TN 37243, USA.
Wesley GeminnTennessee Department of Mental Health & Substance Abuse Services, Nashville, TN 37243, USA.
Marie Chisholm-BurnsOffice of the Provost, Oregon Health & Science University, Portland, OR 97239, USA.
Tennessee Department of Mental Health and Substance Abuse Services · USUniversity of Tennessee Health Science Center · USOregon Health & Science University · USUniversity of Tennessee at Knoxville · USUniversity of Utah · US

Funding

Greater Intermountain Node (CTN-0151)UG1DA049444 · NIDA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Gerald T. Cochran, Adam Joseph Gordon · 2019 to 2026
$16.8M
NIDA NIH HHS UG1 DA049444
6 · The paper itself

Abstract

Community pharmacists have become increasingly exposed to opioid use disorders in recent decades. However, both pharmacist training and traditional practice environments have not been adequate to prepare the pharmacist for both the patient care needs and regulatory barriers of patients experiencing opioid use disorders (OUD). As a result, there is a need to increase pharmacists' awareness of both the overall patient experience as they navigate their OUD and the role of the community pharmacy as a touchpoint within that experience. To this end, a Community-Centered Patient Journey in Drug Addiction Treatment journey map was developed with expert insights, clinical experience, and in-depth interviews (conducted in spring of 2021) with 16 participants enrolled in licensed opioid treatment programs in Tennessee. Patients, policymakers, clinicians, and academic researchers were involved in the map development. Lived experiences of key informants were captured via in-depth interviews. A consensus decision-making approach was used throughout the patient journey map development process. The final patient journey map illustrates a non-linear pathway, describes the central role of the patient's community, and emphasizes three major "pain points" within the system (access, adherence, and affordability). Future research should investigate the impact of such a journey map on pharmacy personnel's knowledge, attitudes, and behaviors.

Indexed as

addictioncommunity pharmacymedications for opioid use disorderpharmacist

Identifiers

PMID36961030
PMCPMC10037586
OpenAlexW4324140764

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read22
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.